Pulmonary arterial hypertension (PAH) is a rare, complex, and progressive disease that is
characterized by the abnormal remodeling of the pulmonary arteries that leads to right …

Patients with comorbidities are often excluded from clinical trials, limiting the evidence base
for pulmonary arterial hypertension (PAH)-specific therapies. This review aims to discuss the …

2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic
pulmonary hypertension | Avdeev | Russian Journal of Cardiology Russian Journal of …

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is a life-threatening
complication of chronic hepatosplenic schistosomiasis. It is suggested to be the leading …

Introduction: Pulmonary hypertension (PH) is a common complication in patients with
congenital heart disease (CHD), aggravating the natural, post-operative, or post …

Background Pulmonary arterial hypertension (PAH) is common in congenital heart disease
(CHD). Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited …

Chronic exposure to cigarette smoke is the major risk factor for the development of
pulmonary hypertension (PH) with chronic lung disease (ie PH group III). The pathogenesis …

Background Pulmonary arterial hypertension (PAH) is characterized by abnormal
proliferation of vascular endothelial and smooth muscle cells and causes occlusion of …

Ulrich, Silvia, Mona Lichtblau, Simon R. Schneider, Stéphanie Saxer, and Konrad E. Bloch,
Clinician's corner: counseling patients with pulmonary vascular disease traveling to high …